α1D-Adrenoceptors are responsible for the high sensitivity and the slow time-course of noradrenaline-mediated contraction in conductance arteries

Pharmacology Research and Perspectives

Volumn 1, Issue 1, 2013, Pages

  Flacco, Nicla ^a   Parés, Jaime ^a   Serna, Eva ^a   Segura, Vanessa ^a   Vicente, Diana ^a   Pérez Aso, Miguel ^a   Noguera, María Antonia ^a   Ivorra, María Dolores ^a   McGrath, John C ^b   D'Ocon, Pilar ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

conductance and resistance vessels; contraction time course; 1A adrenoceptors

Indexed keywords

EID: 84922814335     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.1     Document Type: Article

References (54)

1. Alexander S, Mathie A, Peters J (2011). Guide to receptors and channels (GRAC), 5th edn. Br. J. Pharmacol. 164: S1–S324.
2. Arévalo-León LE, Gallardo-Ortiz IA, Urquiza-Marin H, Villalobos-Molina R (2003). Evidence for the role of alpha1D- and alpha1A-adrenoceptors in contraction of the rat mesenteric artery. Vascul. Pharmacol. 40: 91–96.
3. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, et al. (1997). Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc. Natl. Acad. Sci. USA 94: 11589–11594.
4. Chalothorn D, McCune DF, Edelmann SE, Garcia-Cazarin M, Tsujimoto G, Piascik M (2002). Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol. Pharmacol. 61: 1008–1016.
5. Chen Z, Hague C, Hall RA, Minneman KP (2006). Syntrophins regulate α1D adrenergic receptors through a PDZ domain-mediated interaction. J. Biol. Chem. 281: 12414–12420.
6. Cotecchia S (2010). The alpha1-adrenergic receptors: diversity of signaling networks and regulation. J. Recept. Signal Transduct. Res. 30: 410–419.
7. Daly CJ, Deighan C, McGee A, Mennie D, Ali Z, McBride M, et al. (2002). A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol. Genomics 9: 85–91.
8. Deighan C, Methven L, Naghadeh MM, Wokoma A, Macmillan J, Daly CJ, et al. (2005). Insights into the functional roles of alpha(1)-adrenoceptor subtypes in mouse carotid arteries using knockout mice. Br. J. Pharmacol. 144: 558–565.
9. Docherty JR (2010). Subtypes of functional alpha1-adrenoceptor. Cell. Mol. Life Sci. 67: 405–417.
10. García-Cazarín ML, Smith JL, Olszewski KA, McCune DF, Simmerman LA, Hadley RW, et al. (2008). The alpha1D-adrenergic receptor is expressed intracellularly and coupled to increases in intracellular calcium and reactive oxygen species in human aortic smooth muscle cells. J. Mol. Signal. 3: 6.
11. García-Sainz JA, Torres-Padilla ME (1999a). Modulation of basal intracellular calcium by inverse agonists and phorbol myristate acetate in rat-1 fibroblasts stably expressing alpha1d-adrenoceptors. FEBS Lett. 443: 277–281.
12. García-Sainz JA, Villalobos-Molina R (2004). The elusive alpha(1D)-adrenoceptor: molecular and cellular characteristics and integrative roles. Eur. J. Pharmacol. 500: 113–120.
13. García-Sainz JA, Vázquez-Prado J, Villalobos-Molina R (1999b). Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch. Med. Res. 30: 449–458.
14. Gisbert R, Noguera MA, Ivorra MD, D'Ocon P (2000). Functional evidence of a constitutively active population of alpha(1D)-adrenoceptors in rat aorta. J. Pharmacol. Exp. Ther. 295: 810–817.
15. Gisbert R, Ziani K, Miquel R, Noguera MA, Ivorra MD, Anselmi E, et al. (2002). Pathological role of a constitutively active population of alpha(1D)-adrenoceptors in arteries of spontaneously hypertensive rats. Br. J. Pharmacol. 135: 206–216.
16. Gisbert R, Madrero Y, Sabino V, Noguera MA, Ivorra MD, D'Ocon P (2003a). Functional characterization of alpha 1-adrenoceptor subtypes in vascular tissues using different experimental approaches: a comparative study. Br. J. Pharmacol. 138: 359–368.
17. Gisbert R, Pérez-Vizcaino F, Cogolludo AL, Noguera MA, Ivorra MD, Tamargo J, et al. (2003b). Cytosolic Ca2+ and phosphoinositide hydrolysis linked to constitutively active alpha 1D-adrenoceptors in vascular smooth muscle. J. Pharmacol. Exp. Ther. 305: 1006–1014.
18. Goldstein DS, Eisenhofer G, Kopin IJ (2003). Sources and significance of plasma levels of catechols and their metabolites in humans J. Pharmacol. Exp. Ther. 305: 800–811.
19. Hawrylyshyn KA, Michelotti GA, Cogé F, Guénin SP, Schwinn DA (2004). Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol. Sci. 25: 449–455.
20. Hein P, Michel M (2007). Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal? Biochem. Pharmacol. 73: 1097–1106.
21. Hosoda C, Tanoue A, Shibano M, Tanaka Y, Hiroyama M, Koshimizu TA, et al. (2005). Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice. Br. J. Pharmacol. 146: 456–466.
22. Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, et al. (1999). Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J. Pharmacol. Exp. Ther. 290: 452–463.
23. Hussain MB, Marshall I (1997). Characterization of alpha1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br. J. Pharmacol. 122: 849–858.
24. Keffel S, Alexandrov A, Goepel M, Michel MC (2000). alpha(1)-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 272: 906–911.
25. Kenny BA, Chalmers DH, Philpott PC, Naylor AM (1995). Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol. 115: 981–986.
26. Koshimizu TA, Yamauchi J, Hirasawa A, Tanoue A, Tsujimoto G (2002). Recent progress in alpha 1-adrenoceptor pharmacology. Biol. Pharm. Bull. 25: 401–408.
27. Lachnit WG, Tran AM, Clarke DE, Ford AP (1997). Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br. J. Pharmacol. 120: 819–826.
28. Lyssand JS, DeFino MC, Tang XB, Hertz AL, Feller DB, Wacker JL, et al. (2008). Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosome. J. Biol. Chem. 283: 18792–18800.
29. Lyssand JS, Whiting JL, Lee KS, Kastl R, Wacker JL, Bruchas MR, et al. (2010). Alpha-dystrobrevin-1 recruits alpha-catulin to the alpha1D-adrenergic receptor/dystrophin-associated protein complex signalosome. Proc. Natl Acad. Sci. USA 107: 21854–21859.
30. Lyssand JS, Lee KS, DeFino M, Adams ME, Hague C (2011). Syntrophin isoforms play specific functional roles in the alpha1D-adrenergicreceptor/DAPC signalosome. Biochem. Biophys. Res. Commun. 412: 596–601.
31. Martí D, Miquel R, Ziani K, Gisbert R, Ivorra MD, Anselmi E, et al. (2005). Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am. J. Physiol. Heart Circ. Physiol. 289: H1923–H1932.
32. Martinez-Rivelles S, Caracuel L, Marquez-Martin A, Dantas AP, Oliver E, D'Ocon P, et al. (2012). Increased endothelin-1 vasoconstriction in mesenteric resistance arteries after superior mesenteric ischemia-reperfusion. Br. J. Pharmacol. 165: 937–950.
33. McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJ, et al. (2000). Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists. Mol. Pharmacol. 57: 659–666.
34. Methven L, McBride M, Wallace GA, McGrath JC (2009a). The alpha 1B/D-adrenoceptor knockout mouse permits isolation of the vascular alpha 1A-adrenoceptor and elucidates its relationship to the other subtypes. Br. J. Pharmacol. 158: 209–224.
35. Methven L, Simpson PC, McGrath JC (2009b). Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br. J. Pharmacol. 158: 1663–1675.
36. Michelotti GA, Price DT, Schwinn DA (2000). Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol. Ther. 88: 281–309.
37. Monto F, Oliver E, Vicente D, Rueda J, Aguero J, Almenar L, et al. (2012). Different expressions of adrenoceptors and GRKs in the human myocardium depend on heart failure etiology and correlate with clinical variables. Am. J. Physiol. Heart Circ. Physiol. 303: H368–H376. PMID:22685168
38. Noguera MA, D'Ocon P (1993). Evidence that depletion of internal stores sensitive to noradrenaline elicits a contractile response dependent on extracellular calcium in rat aorta. Br. J. Pharmacol. 110: 861–867.
39. Noguera MA, Ivorra MD, D'Ocon P (1996). Functional evidence of inverse agonism in vascular smooth muscle. Br. J. Pharmacol. 119: 158–164.
40. Pérez-Aso M, Segura V, Montó F, Barettino D, Noguera MA, Milligan G, et al. (2013). The three α1-adrenoceptor subtypes show different spatio-temporal mechanisms of internalization and ERK1/2 phosphorylation. Biochim. Biophys. Acta 1833: 2322–2333.
41. Philipp M, Hein L (2004). Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol. Ther. 101: 65–74.
42. Piascik MT, Perez DM (2001). Alpha1-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. 298: 403–410.
43. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy DL Jr, Perez DM (1995). The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J. Pharmacol. Exp. Ther. 275: 1583–1589.
44. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, et al. (1999). Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100: 2336–2343.
45. Schwinn DA, Page SO, Middleton JP, Lorenz W, Liggett SB, Yamamoto K, et al. (1991). The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol. Pharmacol. 40: 619–626.
46. Stassen FR, Maas RG, Schiffers PM, Janssen GM, De Mey JG (1998). A positive and reversible relationship between adrenergic nerves and alpha-1A adrenoceptors in rat arteries. J. Pharmacol. Exp. Ther. 284: 399–405.
47. Taguchi K, Yang M, Goepel M, Michel MC (1998). Comparison of human alpha1-adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways. Naunyn Schmiedebergs Arch. Pharmacol. 357: 100–110.
48. Tanaka T, Zhang L, Suzuki F, Muramatsu I (2004). Alpha-1 adrenoceptors: evaluation of receptor subtype-binding kinetics in intact arterial tissues and comparison with membrane binding. Br. J. Pharmacol. 141: 468–476.
49. Tanoue A, Koshimizu TA, Tsujimoto G (2002). Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci. 71: 2207–2215.
50. Tanoue A, Koshimizu TA, Shibata K, Nasa Y, Takeo S, Tsujimoto G (2003). Insights into alpha1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol. Metab. 14: 107–113.
51. Theroux TL, Esbenshade TA, Peavy RD, Minneman KP (1996). Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. Mol. Pharmacol. 50: 1376–1387.
52. Yamamoto Y, Koike K (2001). alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br. J. Pharmacol. 134: 1045–1054.
53. Zhong H, Minneman KP (1999). Differential activation of mitogen-activated protein kinase pathways in PC12 cells by closely related alpha1-adrenergic receptor subtypes. J. Neurochem. 72: 2388–2396.
54. Ziani K, Gisbert R, Noguera MA, Ivorra MD, D'Ocon P (2002). Modulatory role of a constitutively active population of alpha(1D)-adrenoceptors in conductance arteries. Am. J. Physiol. Heart Circ. Physiol. 282: H475–H481.